C91.51
Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Adult T-cell lymphoma/leukemia (ATLL) is a rare type of cancer that affects certain white blood cells called T-cells. This condition is linked to an infection with the human T-cell lymphotropic virus type 1 (HTLV-1). When the disease enters remission, symptoms may lessen or become undetectable, but ongoing monitoring is essential. This article provides an overview of ATLL in remission, including its causes, symptoms, diagnosis, and management options.
Causes & Symptoms
Clinical Causes: The primary cause of adult T-cell lymphoma/leukemia is infection with the HTLV-1 virus. HTLV-1 is a retrovirus that can be transmitted through blood transfusions, sexual contact, and from mother to child, typically via breastfeeding. Most individuals infected with HTLV-1 do not develop ATLL; genetic and environmental factors may influence disease progression. The development of ATLL usually takes decades after initial infection, highlighting its slow progression.
Key Symptoms: Swollen lymph nodes, often painless and enlarged. Unexplained weight loss and fatigue. Fever that persists or recurs. Skin lesions or rashes. Persistent infections or infections that are harder to treat. Pain or discomfort in the abdomen due to enlarged organs, such as the spleen or liver. Night sweats and unusual bleeding or bruising.
Diagnostic & Treatment
Diagnosis Path: Blood tests to identify abnormal T-cell populations and detect HTLV-1 antibodies. Imaging studies like CT scans or PET scans to assess the extent of disease. Lymph node or tissue biopsies to examine cellular abnormalities. Bone marrow biopsies if there is suspicion of marrow involvement. Molecular testing to detect genetic changes associated with ATLL.
Treatment Protocols: Continued monitoring and regular follow-up appointments to detect any signs of recurrence. Chemotherapy to eliminate remaining cancerous cells or prevent relapse. Targeted therapies aimed at specific molecular features of ATLL. Supportive care measures to manage symptoms and maintain quality of life. Research into immunotherapies and other novel treatments is ongoing. In some cases, hematopoietic stem cell transplantation might be considered, especially if relapse occurs.
Clinical Advice & FAQs
Billing Guidance
Is C91.51 a billable ICD-10 code?
Yes, C91.51 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.51?
Clinical documentation must specify the nature of Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference